



Kronos Bio Expands Leadership Team with Appointment of Seasoned Drug Discovery Leader Christopher Dinsmore, Ph.D., as Chief Scientific Officer

June 16, 2020

SAN MATEO, Calif. & CAMBRIDGE, Mass.—([BUSINESS WIRE](#))— Kronos Bio, Inc., dedicated to drugging transcriptional regulatory networks in cancer, today announced it has appointed Christopher Dinsmore, Ph.D., as Chief Scientific Officer. He will lead all aspects of the company's discovery organization in Cambridge and will be responsible for advancing preclinical candidates targeting multiple oncogenic transcription regulatory networks.

"Chris brings to Kronos more than 25 years of experience in biomedical research and development, leading innovative research programs and advancing discovery programs from early targets to clinical candidates," said Norbert Bischofberger, Ph.D., President and Chief Executive Officer of Kronos. "His addition to our discovery team will further strengthen our deep expertise in medicinal chemistry, protein homeostasis and structure-based drug design. We look forward to Chris' leadership and contributions to helping us foster innovation and expand our internal discovery pipeline of preclinical oncology programs."

Dr. Dinsmore joined Kronos from Third Rock Ventures, where he was an Entrepreneur-in-Residence, focusing on discovering, launching and building new, innovative therapeutic companies. Prior to that, he served as Vice President and Head of Chemistry at FORMA Therapeutics, where he was responsible for creating and advancing a pipeline of transformative medicines and applying a broad array of discovery chemistry platforms and approaches to target classes in epigenetics and protein homeostasis. Before joining FORMA, he spent 19 years at Merck Research Laboratories, where he held various positions of increasing scientific and managerial leadership in medicinal chemistry, most recently serving as Executive Director, Discovery Chemistry.

"Kronos Bio has made important progress to date in its discovery efforts against a range of validated, historically challenging targets in oncology with its small molecule microarray screening platform," said Dr. Dinsmore. "I am excited to work with the team at Kronos to advance its discovery programs and contribute to the company's efforts to build a robust pipeline of promising anti-cancer therapies."

In 2019, Dr. Dinsmore joined the WARF (Wisconsin Alumni Research Foundation) Therapeutics Advisory Board, where he provides advice on moving therapeutic innovations forward in drug discovery and development. He has co-authored more than 60 publications in chemistry and drug discovery and is a co-inventor on over 70 patents and patent applications. Dr. Dinsmore earned a B.A. in chemistry from Bowdoin College and a Ph.D. in synthetic organic chemistry from the University of Minnesota in Minneapolis. He completed an NIH postdoctoral fellowship in chemical synthesis at Harvard University.

About Kronos Bio, Inc.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription.

For more information, please visit www.kronosbio.com or follow the company on [LinkedIn](#).

###

Contacts

Investor Contact:

Dr Yasir Al-Wakeel
CFO & Head of Corporate Development
media@kronosbio.com

Media Contact:

Sheryl Seapy
W2O pure
+1 213-262-9390
sseapy@purecommunications.com